Pharmaceutical giant Bristol-Myers Squibb Co (NYSE:BMY) stock has performed modestly well year-to-date (YTD), with some steep increases offsetting a few declines. Overall, the stock is expected to continue rising … · 8/25/2015
NEW YORK (TheStreet) -- Bristol-Myers Squibb (BMY - Get Report) stock was upgraded to "neutral" from "underweight" at Piper Jaffray on Monday. When the firm initiated coverage on the stock this June, it viewed the …
The Street · 8/24/2015
Investors in Bristol-Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the October 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BMY options …
NASDAQ · 8/24/2015
More from Bing News
Bristol-Myers Squibb (NYSE:BMY) has been given a consensus recommendation of “Hold” by the twenty ratings firms that are covering the firm, Analyst Ratings Net reports. One investment analyst has rated the …
Ticker Report · 22 hours ago
This featured buy-rated stock has a strong portfolio of oncology and antiviral drugs, which should drive sales growth and margin expansion over the next several years, explain analysts David Toung and Zane Keller of …
The Money Show · 1 day ago
One of the S&P 500’s big winners for Wednesday August 26 was Bristol-Myers Squibb Co. (BMY) as the company’s stock climbed 3.71% to $60.03 on volume of 10.21 million shares. The stock opened at $59.31 and saw an intraday low of $57.75 and …
Equities · 1 day ago
Below is a three month price history chart comparing the stock performance of BMY vs. CVS: According to the ETF Finder at ETF Channel, BMY and CVS collectively make up 6.95% of the PowerShares Dynamic Large Cap Growth Portfolio ETF (PWB) …
Market News Video · 15 hours ago
The stock has lagged far behind such rivals as Pfizer (PFE) and Bristol-Myers Squibb (BMY), trailing each by more than 20 percentage points over the past year. But Merck could be on the cusp of breaking out of its rut.
Kiplinger · 19 hours ago
BMY) in a research report released on Tuesday, ARN reports. The firm currently has a $75.00 price objective on the biopharmaceutical company’s stock. Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 2.
Mideast Times · 8/22/2015
Analyst Richard Purkiss commented, "With shares trading down close to our $61 price target we are upgrading Bristol-Myers Squibb from Underweight to Neutral. We note that the stock has had a significant pullback since the 2Q earnings report and we …
StreetInsider · 8/24/2015
Bristol Myers Squibb

Bristol-Myers Squibb

Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-M…
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
Data from: Wikipedia · Freebase